Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
GlobalData on MSN23h
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
WRAL5d
Weight loss pill could replace injections, would be transformative for millions
Many who would benefit from the drug find the idea of a weekly injection a turnoff. Novo Nordisk's recent announcement that Wegovy in a tablet proved as effective as the shots could open the ...
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
IPWatchdog13d
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...